CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages

The TGFβ receptor inhibitor galunisertib showed promising efficacy in patients with pancreatic ductal adenocarcinoma (PDAC) in the phase 2 H9H-MC-JBAJ study. Identifying biomarkers for this treatment remains essential. Baseline plasma levels of chemokine CCL3 were integrated with clinical outcomes i...

Full description

Saved in:
Bibliographic Details
Published in:NPJ precision oncology 2024-10, Vol.8 (1), p.246-15, Article 246
Main Authors: Pietrobono, Silvia, Bertolini, Monica, De Vita, Veronica, Sabbadini, Fabio, Fazzini, Federica, Frusteri, Cristina, Scarlato, Enza, Mangiameli, Domenico, Quinzii, Alberto, Casalino, Simona, Zecchetto, Camilla, Merz, Valeria, Melisi, Davide
Format: Article
Language:English
Subjects:
631/67/1059/602
692/4028/67/1504/1713
692/53/2423
Biomarkers
Cancer Research
Cancer therapies
Chemokines
Gene Therapy
Human Genetics
Internal Medicine
Medical prognosis
Medicine
Medicine & Public Health
Metastasis
Oncology
Pancreatic cancer
Signal transduction
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The TGFβ receptor inhibitor galunisertib showed promising efficacy in patients with pancreatic ductal adenocarcinoma (PDAC) in the phase 2 H9H-MC-JBAJ study. Identifying biomarkers for this treatment remains essential. Baseline plasma levels of chemokine CCL3 were integrated with clinical outcomes in PDAC patients treated with galunisertib plus gemcitabine ( n  = 104) or placebo plus gemcitabine ( n  = 52). High CCL3 was a poor prognostic factor in the placebo group (mOS 3.6 vs. 10.1 months; p  
ISSN:2397-768X
2397-768X
DOI:10.1038/s41698-024-00742-3